The AHA’s Takes Aim at the Hospital-Prices-Are-Too-High Narrative ... and Misses

And two useful correctives to the White House’s myopic views on how international reference pricing works in the real world

The Top 10 News Items Today Are Dominated by 340B, with MFN, Affordability, and PBMs Also on the Agenda

And a podcast recommendation on the coming challenges in oncology

What the White House’s Vastly Inflated MFN Savings Numbers Really Tell Us

Running the Numbers on Pharm-to-Table in Obesity, Cholesterol Management

And industry gets a win in a 340B “STD loophole” case

Maine Is a Battleground State. Cue the Less-Than-Constructive Healthcare Ads.

And there is bipartisan consensus on the most divisive issue in health care [sic]

Are Pharma CEOs Talking MFN During Earnings Season? Depends On Who You Ask.

Plus, launching the quarterly Apex tracker of CEO earnings commentary

Prescriptions for an 11-Year-Old Drug for Female Libido Just Doubled, and Pharm-to-Table Played a Role

And Elizabeth Warren’s inquiry into TrumpRx asks the exact questions I’m interested in

It’s Increasingly Clear That MFN Will Impact Europe First

And the votes are in on the “healthcare” vs “health care” debate ...

Regeneron’s Free Gene Therapy, Six New Meds to TrumpRx (and One to Mark Cuban), and the Ten Other Stories to Track Today

And I need your vote on an issue of huge significance

APEX Special Edition: 340B Is Having a Week. These 10 Stories Prove It.

The Three Most Interesting Things RFK Jr. Said About Drug Prices This Week

And we know that CMS will pay for obesity meds in Medicare through 2027. But what about 2028 ... and beyond?

Having Lost Its BALANCE, CMS Is Now Walking Across a ‘Bridge’ To Obesity Coverage in Medicare

And BMS’ pricing transparency data is out, showing that net prices continue to fall

Off-BALANCE: The Effort to Bring Obesity Meds Into Medicare Hits a Snag as Major Payers Express Doubts

And United had a blowout earnings release. Its PBM, Optum Rx? Not so much.

It’s Decision Day for Health Plans: Will They Opt to Cover Obesity Meds in Medicare?

And more evidence that prior authorization decisions are often delayed

Medicare Coverage of Obesity Drugs Hangs in the BALANCE

I'm looking for your vote on whether the CMS pilot will move forward

Bernie and RFK Jr. Are Making Noise on the Hill Today. Don’t Feel Compelled to Listen.

And a sampling of the comments on a Labor Department proposal to rein in PBMs

Listing the New Additions to TrumpRx, From Least Surprising to Most Eyebrow-Raising

And the majority of new prescriptions written get rejected by commercial plans, IQVIA analysis finds

A Spring Reading List of Essential Research and Analyses

CMS Targets Prior Auth Timelines for Medicines, Though High Denial Rates May Be the Bigger Issue

And BIO’s leader expresses concern about the MFN choices smaller biotechs must make

A New Poll Underscores Patient Interest – and Payer Risk – in Medicare Coverage of GLP-1s for Obesity

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

PCMA Survey Says Employers Love Their PBMs. But There Are Reasons to Be Skeptical.

A New Analysis Makes Clear How Expensive It Will Be for Plans to Add Obesity Meds to Medicare

Plus, the crossover event of the year: TrumpRx is driving traffic to Mark Cuban Cost Plus Drugs

Looking Past the Tariff Headlines to Focus on Where the Impact Is ... and Is Not

And the White House budget proposal includes a huge boost in funding to oversee 340B